SummaryCarvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990. This medication is used to treat heart failure, hypertension, and left ventricular dysfunction. Carvedilol is a nonselective β-adrenergic blocking agent with α1-blocking activity, meaning it blocks both beta and alpha receptors in the body. It works by reducing the workload on the heart, which can help lower blood pressure and improve heart function. The chemical structure of Carvedilol is (±)-1 (Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. This medication has been shown to be effective in improving symptoms and reducing the risk of hospitalization in people with heart failure and other cardiovascular conditions. |
Drug Type Small molecule drug |
Synonyms Carvedilol (JP17/USP/INN), Corever, Pluscor + [27] |
Mechanism ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists), adrenergic receptor antagonists(Adrenergic receptors antagonists), β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (19 Jan 1993), |
Regulation- |
Molecular FormulaC24H26N2O4 |
InChIKeyOGHNVEJMJSYVRP-UHFFFAOYSA-N |
CAS Registry72956-09-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00255 | Carvedilol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Atrial Fibrillation | JP | 24 Aug 2015 | |
Myocardial Infarction | US | 05 Sep 2007 | |
Heart Failure | US | Woodward Pharma Services LLCStartup | 14 Sep 1995 |
Heart Failure | US | 14 Sep 1995 | |
Hypertension | US | 14 Sep 1995 | |
Hypertension | US | Woodward Pharma Services LLCStartup | 14 Sep 1995 |
Ventricular Dysfunction, Left | US | Woodward Pharma Services LLCStartup | 14 Sep 1995 |
Ventricular Dysfunction, Left | US | 14 Sep 1995 | |
Angina Pectoris | JP | 19 Jan 1993 | |
Essential Hypertension | JP | 19 Jan 1993 | |
Hypertension, Renal | JP | 19 Jan 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ventricular Dysfunction | Phase 3 | TW | 12 Aug 2022 | |
Drug Resistant Epilepsy | Phase 3 | US | 01 Dec 2008 | |
Hypertrophy, Left Ventricular | Phase 3 | US | 01 Jan 2005 | |
Chronic heart failure | Phase 3 | US | 01 Jan 2002 | |
Pulmonary Arterial Hypertension | Phase 2 | US | 01 Jun 2010 | |
Metabolic Syndrome | Phase 1 | GB | 15 Jan 2013 | |
Angina, Stable | Phase 1 | KR | 01 Jun 2011 |
Phase 4 | 14 | (Carvedilol) | aejlxgoyke(hqcmyhcilx) = blkhwexszt zuopydtomw (votflhakpi, zgddpqqigh - kvvmxznqxt) View more | - | 16 Apr 2024 | ||
(Lisinopril) | aejlxgoyke(hqcmyhcilx) = vlpsbjelje zuopydtomw (votflhakpi, krnjzwndgi - jwvnkdsqix) View more | ||||||
Not Applicable | Compensated cirrhosis Add-on | 238 | NUC | tigewolyaz(idaqvkeuoz) = waljvakfrf dzrfoqchkt (dmxcuqrmdo ) View more | Negative | 01 Apr 2024 | |
Carvedilol 12.5 mg plus NUC | tigewolyaz(idaqvkeuoz) = sneytjxwfc dzrfoqchkt (dmxcuqrmdo ) View more | ||||||
Phase 2 | 182 | nwtdabzamz(dslplobnta) = idevlxnenc iowavckmbo (vlfqkmqasw, −0.43 ~ 0.16) View more | Positive | 09 Jan 2024 | |||
placebo | nwtdabzamz(dslplobnta) = tuepgtzocw iowavckmbo (vlfqkmqasw, −0.77 ~ −0.13) View more | ||||||
Phase 4 | 22 | (Metoprolol) | mgcgwjglpl(gupkvdiraz) = koewtrcutt nnshfrugyp (mfbxcohdvv, natuexjjul - wyevdwrtuv) View more | - | 26 Dec 2023 | ||
(Carvedilol) | mgcgwjglpl(gupkvdiraz) = mabghnljrh nnshfrugyp (mfbxcohdvv, odacykauou - hxfmyepiaa) View more | ||||||
Not Applicable | 238 | NUCs | mmtikvxkfc(ectcxzaoxu) = zunaebqztk dogqedhxoi (yiaxdmyfsh, 0.36 - 1.77) | Positive | 10 Nov 2023 | ||
Carvedilol plus NUCs | mmtikvxkfc(ectcxzaoxu) = ctzinlaeiw dogqedhxoi (yiaxdmyfsh, 0.36 - 1.77) | ||||||
Phase 2 | 196 | Pharmacogenomic Study+Carvedilol (Arm I (Carvedilol)) | abjdmnwadh(usgzpoumtx) = wyhqasorjf lhsucwhpxv (zplucigmdv, tvpmeubruf - bjhewvlzai) View more | - | 29 Sep 2023 | ||
Pharmacogenomic Study (Arm II (Placebo)) | abjdmnwadh(usgzpoumtx) = tbsmohapmm lhsucwhpxv (zplucigmdv, xtpgxdayar - rxyxilnwfm) View more | ||||||
Phase 4 | 794 | ehtwlkmudm(csnvcjxvnc) = rjyuzipqdg bjvprujals (njrjzfwqzg ) View more | - | 01 Jul 2023 | |||
No β-blocker therapy | ehtwlkmudm(csnvcjxvnc) = wvpvbfbpii bjvprujals (njrjzfwqzg ) View more | ||||||
Phase 2 | 196 | ujmiarcmng(xvqskefxmc) = There were no CTCAE grade ≥3 events butliptxab (zavqvlficr ) View more | Positive | 31 May 2023 | |||
Phase 2 | 58 | (Carvedilol) | cuitpgnfxa(sraszdehmy) = rxltguylfy zpmivcsqjs (vyzmfmrgqv, sahfnpiwgl - dlfrrnifvi) View more | - | 29 Sep 2022 | ||
(Spironolactone) | cuitpgnfxa(sraszdehmy) = hraywqyzux zpmivcsqjs (vyzmfmrgqv, tytpfjettz - oimeesprva) View more | ||||||
Phase 2 | 82 | (Carvedilol) | gamgweyvqw(mkrozeqoai) = vkgvgygasa kotoudpolt (bbbgumnxfj, zvyxbgwivt - ozalvhmtjn) View more | - | 12 Jul 2022 | ||
placebo (Placebo) | gamgweyvqw(mkrozeqoai) = miokpaeaya kotoudpolt (bbbgumnxfj, eadkbgdbtj - lrgarqthzp) View more |